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The group B Coxsackieviruses (CVB), belonging to the Enterovirus genus, can establish persistent in-
fections in human cells. These persistent infections have been linked to chronic diseases including
type 1 diabetes. Still, the outcomes of persistent CVB infections in human pancreas are largely un-
known. We established persistent CVB infections in a human pancreatic ductal-like cell line PANC-1
using two distinct CVB1 strains and profiled infection-induced changes in cellular protein expression
and secretion using mass spectrometry-based proteomics. Persistent infections, showing characteris-
tics of carrier-state persistence, were associated with a broad spectrum of changes, including changes
in mitochondrial network morphology and energy metabolism and in the regulated secretory
pathway. Interestingly, the expression of antiviral immune response proteins, and also several other
proteins, differed clearly between the two persistent infections. Our results provide extensive infor-
mation about the protein-level changes induced by persistent CVB infection and the potential virus-
associated variability in the outcomes of these infections.
INTRODUCTION
Enteroviruses are the most common human viruses, causing a wide spectrum of diseases ranging frommild
common cold-type illness to severe life-threatening conditions. Polioviruses causing paralytic diseases are
their most well-known representatives (Laitinen et al., 2016). The group B Coxsackieviruses (CVBs) are
among those enteroviruses that most frequently lead to contacts with the health care system causing,
e.g., meningitis, encephalitis, myocarditis, hand-foot-and-mouth disease, pancreatitis, and hepatitis (Tap-
parel et al., 2013). Young children are at the highest risk of developing severe CVB diseases, and infection in
newborn infants can lead to life-threatening systemic infections. CVB infections are typically acute, and the
host’s immune system clears the virus within a few days or weeks. CVBs can, however, also establish chronic
(persistent) infections (Chapman and Kim, 2008; Pinkert et al., 2011; Sane et al., 2013), which have been
linked to chronic diseases including type 1 diabetes (T1D) and dilated cardiomyopathy (Nurminen et al.,
2012; Massilamany et al., 2014; Hyoty, 2016).
CVBs are small, non-enveloped viruses, and their positive-sense single-stranded RNA genome is inside the
icosahedral protein capsid (Tuthill et al., 2010). There are six different CVB serotypes (CVB1–6) that can be
separated from each other based on their antigenic and genetic properties. The viral genome encodes for
viral structural proteins, VP1–4, and seven non-structural proteins, 2A–2C and 3A–3D. The infection cycle
starts by the attachment of the virus to the cell surface receptor followed by viral entry into the cell (Tuthill
et al., 2010). The viral RNA genome is released by uncoating and is transported into the cytoplasm where it
is transcribed and translated. Finally, mature virions are released, usually by lysis of infected cells (Laitinen
et al., 2016).
The mechanisms leading to enteroviral persistency are not fully understood. However, it appears that the
development of viral persistency is linked to a complex co-evolutionary process of both the host cell and
the virus (Alidjinou et al., 2017; Pinkert et al., 2011). Studies in cell and animal models suggest that there are
two types of persistent infections, called carrier-state and steady-state persistence. In a steady-state infec-
tion the viral replication cycle is non-lytic and a large proportion of cells can be simultaneously infected
(Frisk, 2001). In a carrier-state infection high titers of virus are produced, but only a small proportion of340 iScience 19, 340–357, September 27, 2019 ª 2019 The Author(s).
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the cells are infected (Alidjinou et al., 2017; Pinkert et al., 2011). Kim et al. have established a steady-state
infection with CVB3 in primary cells isolated from different tissues including human cardiac myocytes and
mouse heart and pancreatic cells (Kim et al., 2008). Infection did not cause cell lysis, even though viral RNA
was produced. However, the viral genome harbored 7- to 49-nucleotide-long deletions in the untranslated
region in the 50 end (Kim et al., 2008), which may explain the non-lytic character of the virus. Carrier-state
CVB3 infection has been established in murine cardiac myocyte cell line, HL-1 (Pinkert et al., 2011). Another
carrier-state infection model has been established in pancreatic duct cell line, PANC-1, using CVB4 (Sane
et al., 2013). The viral plaquemorphology changed, and several mutations accumulated in the viral genome
during the development of persistent infection. The persistently infected cells also became resistant to the
cytopathic effect induced by CVB4 re-infection (Alidjinou et al., 2017). The CVB receptor coxsackievirus and
adenovirus receptor (CXADR) was downregulated in these carrier-state models, which may contribute to
the resistance of persistently infected cells to superinfection by other CVBs and to the lack of fulminant
cytopathic effect (Alidjinou et al., 2017; Pinkert et al., 2011). Finally, previous studies have suggested
that individual strains of a given CVB type can differ in their effects on target cells and in their ability to
induce antiviral host responses (Anagandula et al., 2014; Hamalainen et al., 2014; Ylipaasto et al., 2012).
Such differences might also influence how efficiently the infection is eradicated and the persistence of
the virus in the infected cells or organs.
Pancreas is an important target organ of CVBs, which can infect both exocrine and endocrine cells of human
pancreas (Busse et al., 2017; Richardson et al., 2009). A role for CVBs in the pathogenesis of T1D is sup-
ported by the strong expression of CXADR in insulin-producing pancreatic beta-cells (Ifie et al., 2018)
because CVBs, but no other enteroviruses, use this receptor to enter the cell. Enterovirus VP1 protein
has been repeatedly detected in the beta-cells of patients with T1D (Krogvold et al., 2015; Richardson
et al., 2009, 2013). However, only few beta-cells express viral protein and the amount of viral RNA is low,
consistent with a low-grade viral persistence rather than an acute productive infection. CVBs have also oc-
casionally been detected outside of pancreatic islets in human pancreas tissue samples (Busse et al., 2017;
Richardson et al., 2009; Ylipaasto et al., 2004). Interestingly, a small set of data based on a novel and sen-
sitive approach for detecting CVB RNA indicated the presence of these viruses outside pancreatic islets
also in tissue biopsies collected from individuals with T1D (Busse et al., 2017). The association between
CVBs and T1D has been documented in prospective birth cohort studies already before the beta-cell
damaging process has started (Laitinen et al., 2014; Oikarinen et al., 2014; Sioofy-Khojine et al., 2018), sug-
gesting that these viruses can play a role in the initiation of the process. Among the six CVB types, CVB1
and CVB4 have most frequently been associated with T1D (Laitinen et al., 2014; Oikarinen et al., 2014;
Sioofy-Khojine et al., 2018; Yoon et al., 1979).
The present study aims at identifying cellular responses during persistent CVB infection and understanding
the mechanisms mediating the adaptation of cells to the carrier-type persistence. Establishing long-term
CVB persistency in primary human pancreatic islets (Chehadeh et al., 2000) or insulin-producing beta-cell
lines is challenging. Here we utilized a well-established model of persistent CVB infection in PANC-1 cells
(Sane et al., 2013) for broad mapping of infection-induced changes in protein expression and secretion af-
ter almost 1 year’s persistency. Persistent infections were established by using two distinct strains of CVB1,
an enterovirus that has been previously associated with T1D in epidemiological studies (Laitinen et al.,
2014; Oikarinen et al., 2014; Sioofy-Khojine et al., 2018). In our previous study (Hamalainen et al., 2014),
these two strains differed by the strength of innate immune responses they induced. Infection-associated
changes in intracellular proteomes and secretomes were profiled using quantitative mass spectrometry-
based proteomics.RESULTS
Coxsackievirus B1 ATCC and 10796 Strains Establish Persistent Infections in PANC-1 Cells
Persistent CVB1 infection was established in the PANC-1 human pancreatic duct cell line using two virus
strains (ATCC and 10796). We observed a strong cytopathic effect immediately after the initial infection
with both CVB strains, and the amount of viral RNA in cell culture supernatants, measured by RT-qPCR,
dropped dramatically at this point, likely due to the rapid loss of cells that could support viral replication.
Restored proliferation in the surviving cells was associated with an increased amount of viral RNA reaching,
in both models, 108 copies per sample approximately 3 months after the initial infection (Figure 1A). There-
after, the copy number of viral RNA remained stable. Around a year after the initial infection, the viral capsid
protein VP1 was detected by immunohistochemical (IHC) staining (Figure 1B), and both establishedmodelsiScience 19, 340–357, September 27, 2019 341
Figure 1. Establishment of Persistent CVB1 Infections in PANC-1 Cells
(A) Both CVB1 strains (ATCC and 10796) were replicating in PANC-1 cells for nearly 1 year. The amount of viral RNA was
measured by RT-qPCR, and the results were converted into genome copy numbers/sample (140 mL). Sample collection for
proteomics was performed 300, 315, and 322 days post-infection, as indicated in the figure.
(B) Viral capsid protein VP1 (brown) was detected by IHC at 362 days post-infection. Scale bar, 25 mm.showed features of carrier-state persistent infection with a low proportion of the cells clearly positive for
viral VP1 protein (Alidjinou et al., 2017; Pinkert et al., 2011). The proteomes of these persistently infected
cells were analyzed at this time. Persistent CVB1 infections were not associated with increased cell death
(Table S1).
Persistent Coxsackievirus B1 Infection Results in Extensive Changes in Protein Expression
and Secretion
Using mass spectrometry-based proteomics, we identified and quantified altogether 5,130 distinct protein
groups in the cell lysates and 3,181 distinct protein groups in the cell culture supernatants of the PANC-1
cells (Tables S2 and S3). Persistent CVB1 infections were associated with extensive changes in intracellular
protein expression and protein secretion. Significant upregulation of 688 distinct protein groups was
observed in PANC-1 cells with persistent CVB1 infection, with 85 of the protein groups significantly upre-
gulated in both persistent CVB1 infection models (Figures 2A and 2B). Furthermore, persistent CVB1 infec-
tions were associated with significant downregulation of 2,001 distinct protein groups in the PANC-1 cells,
with 520 of the protein groups significantly downregulated in both persistent infection models (Figures 2A
and 2B). Finally, significant upregulation of 919 distinct protein groups and significant downregulation of
630 distinct protein groups was observed in the cell culture supernatants of the persistent CVB1 infection
models (Figure 2C). Of them, the secretion of 166 and 197 distinct protein groups was significantly upregu-
lated and downregulated in both persistent CVB1 infection models, respectively (Figures 2C and 2D).
Proteins Potentially Involved in Viral Replication and Spreading Were Influenced during
Persistent CVB1 Infection
Downregulation of a broad spectrum of host proteins was observed in the PANC-1 cells in both persistent
CVB1 infectionmodels (Figures 2A and 2B). CVB proteinase 2A can block the host cell translational machin-
ery and promote viral IRES-driven translation via cleavage of host translation initiation factor eIF4G342 iScience 19, 340–357, September 27, 2019
Figure 2. Persistent CVB1 Infection Results in Changes in Intracellular Protein Expression and Protein Secretion
(A) Numbers of differentially expressed proteins in cells with persistent CVB1 ATCC and 10796 infection.
(B) Heatmap of Z-score normalized data for the 605 proteins with similar responses to persistent CVB1 infection with both
virus strains in the PANC-1 cells.
(C) Numbers of proteins whose secretion is significantly changed during persistent CVB1 ATCC and 10796 infections.
(D) Heatmap of Z-score normalized data showing the 363 proteins whose secretion is changed similarly from cells with
persistent CVB1 ATCC and 10796 infections.required for cap-dependent translation (Borman et al., 1997). Indeed, western blot analysis showed the
presence of cleaved eIF4G in both persistent CVB1 infection models (Figure 3A). Based on Ingenuity
Pathway Analysis (IPA), proteins involved in cholesterol biosynthesis pathways and the mevalonate
pathway, which provides building blocks for cholesterol biosynthesis, were significantly enriched among
the upregulated proteins in both persistent infection models (Figure 3B, Table S4). Cholesterol is known
to facilitate efficient CVB replication, and CVBs manipulate host cell cholesterol shuttle to accumulate
this lipid in viral replication organelles (Albulescu et al., 2015; Ilnytska et al., 2013). Poly(rC)-binding protein
2 (PCBP2) is essential for CVB IRES-mediated translation and viral RNA replication (Sean et al., 2009), and itsiScience 19, 340–357, September 27, 2019 343
Figure 3. Both Persistent CVB1 Infections Modulate the Expression of Multiple Host Cell Proteins
(A) eIF4G is cleaved in PANC-1 cells with persistent CVB1 ATCC and 10796 infection. Western blot analyses were performed for two biological replicates
from each condition.
(B) IPA canonical pathways that are significantly enriched among the upregulated proteins in both persistent CVB1 infection models.
(C) Several nuclear complex proteins are downregulated during persistent CVB1 infection. Nuclear pore complex proteins were assigned based on
Knockenhauer and Schwartz (2016). *FDR < 0.05 and |Fold change|R 1.5.
(D) Raw intensities of three CXADR peptides in the PANC-1 cells. For each sample, median intensity of three technical replicates is shown.
(E) IPA canonical pathways that are significantly enriched among the downregulated proteins in both persistent CVB1 infection models. FDR, false discovery rate.expression was significantly upregulated in both persistent CVB1 infectionmodels (Table S2). In addition to
PCBP2, other host RNA-binding proteins also can improve the replication of CVB viruses. Interfering with
the cell’s nucleocytoplasmic trafficking can hinder the transport of these proteins from the cytoplasm to the
nucleus making them more accessible for the virus replicating in the cytoplasm (Belov et al., 2000; Gustin344 iScience 19, 340–357, September 27, 2019
and Sarnow, 2001). In the current study, several proteins of the nuclear pore complex responsible for pro-
tein nucleocytoplasmic trafficking were significantly downregulated in both persistent infection models
(Figure 3C).
Several viral peptides were identified in the cells and the cell culture supernatants of the persistent CVB1
infection models, supporting the presence of actively replicating virus still more than 300 days after the
initial infection (Table S5). Interestingly, higher expression of viral proteins was detected in the cells and
the cell culture supernatants during persistent infection with 10796 strain of CVB1 when compared with
CVB1 ATCC infection model (Table S5). Here, the viral protein expression in each sample was defined as
the sum of intensities for peptides mapping to genome polyprotein sequence of CVB1 Japan strain
(UniProtKB: P08291), which is the only manually curated CVB1 protein sequence available in the SwissProt
database.
Downregulation of the CVB receptor CXADR has been a common feature for carrier-state persistent CVB
infections (Alidjinou et al., 2017; Pinkert et al., 2011). In line with these studies, CXADR protein expression
was only detected in the non-infected PANC-1 cells (Figure 3D, Table S2), suggesting its downregulation
during persistent CVB1 infection. However, neither of the persistent CVB1 virus strains lose their ability to
use CXADR receptor in the entry, because they infected CAR-transfected CHO cells but were unable to
infect naive CHO cells (data not shown). Furthermore, proteins involved in virus entry via the endocytic
pathways were enriched among the downregulated proteins in both persistent infection models based
on IPA analysis (Figure 3E, Table S4), indicating also a broader downregulation of proteins potentially
involved in viral entry during persistent CVB1 infection. These changes are likely to limit the spreading
of the virus from cell to cell during persistent infection.
Persistent CVB1 Infections Are Associated with Changes in Mitochondrial Energy
Metabolism and Network Morphology
One of the main features of the persistent CVB1 infection models was the significant downregulation of
mitochondrial proteins, especially those proteins involved in mitochondrial energy metabolism (Figure 3E,
Tables S4 and S6). Downregulation of mitochondrial energy metabolism has earlier been observed in
mouse models of cardiomyopathy associated with chronic CVB3 infection (Nishtala et al., 2011; Xu et al.,
2011). Mitochondrial oxidative phosphorylation was among the three most significantly downregulated
pathways in both persistent infection models (Figure 3E) with 27 and 42 oxidative phosphorylation chain
components downregulated by ATCC and 10796 strains of CVB1, respectively. In addition, for example,
pathways of fatty acid beta-oxidation, citric acid cycle, and leucine and valine degradation were signifi-
cantly enriched among the downregulated proteins in both models (Figure 3E, Table S4).
To get a deeper view on persistent CVB1 infection-induced mitochondrial changes, mitochondrial networks in
the PANC-1 cells were visualized using MitoTracker staining, which labels active mitochondria based on mito-
chondrial membrane potential (Figure 4A). Mitochondrial network morphology is highly responsive to the exist-
ing conditions and influences cellular metabolism and several other signaling pathways (Wai and Langer, 2016).
The stained cells were subdivided into four different categories based on themorphology of their mitochondrial
network: elongated filaments, filaments, intermediate, and fragmented network. A highproportion (44%G 14%,
p < 0.01) of the cells persistently infected with 10796 strain of CVB1 showed fragmentedmitochondrial network,
whereas the majority of the uninfected control cells and cells infected with the ATCC strain of CVB1 showed fila-
mentous networks (Figure 4B). Further supporting these results, proteomics analyses showed the significant
downregulation of three proteins with central roles in mitochondrial fusion processes, namely, mitofusin 1, mi-
tofusin 2 (MFN1 andMFN2), and dynamin-like 120-kDa mitochondrial protein (OPA1) (Wai and Langer, 2016), in
the CVB1 10796 persistent infection model.
Classical and Unconventional Protein Secretion from PANC-1 Cells Is Modulated by
Persistent CVB1 Infection
Persistent CVB1 infections changed significantly the secretion of 1,483 proteins from the PANC-1 cells. Of
these, 623 proteins were associated with extracellular exosomes based on their Gene Ontology annota-
tions (Table S6), indicating that they might be secreted from the cells by unconventional vesicle-mediated
mechanisms. The tetraspanin family of proteins is highly enriched in the membranes of exosomes (Andreu
and Ya´n˜ez-Mo´, 2014), and three members of this family (CD63, CD81 and CD9), held as classical exosome
markers, were also detected in the current study (Table S3). The levels of CD63 were significantlyiScience 19, 340–357, September 27, 2019 345
Figure 4. Mitochondrial Networks in Non-infected PANC-1 Cells and Cells with Persistent CVB1 Infections
Cell imaging analysis was carried out on three biological replicates of CVB1 ATCC persistent infection model and four
biological replicates of CVB1 10796 persistent infection model and non-infected control cells.
(A) Mitochondrial network is visualized in living cells using MitoTracker staining. Representative examples of cells with
persistent CVB1 ATCC and 10796 infection and non-infected control cells are shown.
(B) Cells were grouped into four different categories based on the morphology of their mitochondrial network. The data
are presented as meanG SD. Total numbers of cells used for the grouping: control N = 784, CVB1 ATCC N = 546, CVB1
10796 N = 709.downregulated in the cell culture supernatants of the CVB1 ATCCmodel, whereas the secretion of another
exosome marker, CD9, was significantly downregulated in cells persistently infected with CVB1 10796
strain. The persistent CVB1 infections did not change the secretion of CD81 (Figure 5A).
Based on SignalP analysis (Petersen et al., 2011), 371 differentially expressed proteins in the cell culture
supernatants carry a signal peptide and are therefore likely to be secreted via the classical endoplasmic
reticulum (ER)-Golgi pathway. Coxsackievirus proteins have previously been reported to inhibit protein
trafficking through the Golgi (Cornell et al., 2006; de Jong et al., 2006), and in the current study the secre-
tion of 225 and 218 proteins with predicted signal peptide was also downregulated in cells with persistent
CVB1 ATCC and 10796 infection, respectively. Of those proteins 135 were commonly downregulated in the
cell culture supernatants of CVB1 ATCC- and 10796-infected PANC-1 cells, whereas only five proteins with
a predicted signal peptide were upregulated in the cell culture supernatants of both persistent infection
models. One of these five upregulated proteins was macrophage colony stimulating factor 1 (CSF1), a cyto-
kine with increased production reported in mouse heart tissues at the acute state of CVB3-inducedmyocar-
ditis (Meyer et al., 2018).
In particular, persistent CVB1 infection was associated with clearly downregulated secretion of all five gra-
nin family members detected in the present study: chromogranin-B (also called secretogranin-1) (CHGB),
secretogranin-2 (SCG2), secretogranin-3 (SCG3), neurosecretory protein VGF (VGF), and ProSAAS
(PCSK1N) (Figures 5B and 5C). The granin family members have essential roles in the regulated secretory346 iScience 19, 340–357, September 27, 2019
Figure 5. Persistent CVB1 Infection Influences the Secretion of Several Proteins
(A) Secretion of exosome marker proteins CD9, CD63, and CD81 from PANC-1 cells. For each sample, the median
intensity of three technical replicates is shown. Statistically significant differences are marked with *.
(B and C) Persistent CVB1 ATCC (B) and 10796 (C) infection induced changes in the levels of extended granin family
proteins, CPE and peptidylglycine a-amidating monooxygenase (PAM) in the cell culture supernatants.
(D–F) RT-qPCR analyses of CHGB (D), SCG3 (E), and CPE (F) in PANC-1 cells. The measurements were performed for the
three biological replicates from each condition, and results are shown as Delta CtG SD. Primer sequences are presented
in Table S7.pathway, which is responsible of rapid on-demand secretion of hormones, growth factors, neurotransmit-
ters, and other molecules. Proteins secreted through this pathway are directed from the trans-Golgi
network to dense core granules, where they are stored at high concentrations until an extracellular signal
stimulates their secretion. The granin family members present critical roles in the regulated secretoryiScience 19, 340–357, September 27, 2019 347
Figure 6. Persistent CVB1 Infections Influence the Expression of Several Proteins Associated with Beta-Cell
Differentiation, Growth, and Survival
Persistent CVB1 infection induced changes in the expression levels of (A) ALDH1A3 (cell lysates), (B) SPARC (cell culture
supernatants), (C) SUSD2 (cell lysates), and (D) HSPG2 (cell lysates). For each sample, median intensity of the three
technical replicates is shown. Statistically significant differences are marked with *. ND, not detected.pathway especially in granule biogenesis and protein sorting and also give rise to biologically active pep-
tides (Huh et al., 2003; Hosaka et al., 2004; Courel et al., 2010; Bartolomucci et al., 2011). In addition to the
granin family members, two well-known processing enzymes present in the regulated secretory pathway,
peptidylglycine a-amidating monooxygenase (PAM) and carboxypeptidase E (CPE) (Eipper et al., 1993; Ji
et al., 2017), were clearly downregulated or undetectable in the cell culture supernatants of the persistently
CVB1-infected cells (Figures 5B and 5C). Further RT-qPCR analyses showed the downregulation of the gra-
nin family members CHGB and SCG3 already at transcriptional level, whereas the processing enzyme CPE
remained undetectable at mRNA level in cells with persistent CVB1 ATCC infection but was significantly
upregulated at mRNA level in cells with persistent CVB1 10796 infection (Figures 5D–5F). In summary,
our results indicate that persistent CVB1 infections can interfere with protein secretion from the cells at mul-
tiple different levels.
Proteins Associated with Pancreatic Beta-Cell Differentiation and Survival Are Strongly
Affected by Persistent Coxsackievirus B1 Infection
Acute virus-like infection induces dedifferentiation in a human beta-cell line (Oshima et al., 2018). On the
other hand, persistent CVB4 infection of PANC-1 cells downregulates the transcription factor PDX1, which
is important for the formation of the endocrine pancreas (Sane et al., 2013). Interestingly, some of the pro-
teins with the strongest infection-associated changes in the PANC-1 cells in the current study have also
been linked with pancreatic beta-cell differentiation or survival. Furthermore, clear differences in the
expression of a few of these proteins were observed between the two persistent infection models.
The most strongly upregulated protein in cells with persistent CVB1 ATCC infection was aldehyde dehy-
drogenase 1a3 (ALDH1A3), which has been used as amarker of dedifferentiated pancreatic beta-cells (Cinti
et al., 2016; Kim-Muller et al., 2016). On the other hand, ALDH1A3 was not detected at all in cells with persis-
tent CVB1 10796 infection, indicating its downregulation in this persistent infection model (Figure 6A). Ma-
tricellular protein SPARC is secreted by the cells of the endocrine and exocrine pancreas, and it can have a
negative impact on beta-cell growth and survival (Ryall et al., 2014). It was the fourth most strongly upregu-
lated protein in cells with persistent CVB1 ATCC infection, and its secretion from these cells was also signif-
icantly upregulated (Figure 6B). Similarly to ALDH1A3, SPARC was not detected in cells with persistent
CVB1 10796 infection, and its secretion was strongly downregulated during persistent infection with
CVB1 10796. Upregulation of the sushi domain-containing protein 2 (SUSD2) has been used to mark a
particular stage in the maturation of endocrine pancreas during human fetal pancreatic differentiation348 iScience 19, 340–357, September 27, 2019
(Ramond et al., 2017). In the current study, SUSD2 was the third most strongly upregulated protein in cells
persistently infected with CVB1 10796 strain, whereas its expression was significantly downregulated in the
cells with persistent CVB1 ATCC infection (Figure 6C). Finally, heparan sulfate proteoglycan core protein
(HSPG2) was the most strongly downregulated protein in cells with persistent CVB1 10796 infection,
whereas it was not differentially expressed in cells with persistent CVB1 ATCC infection (Figure 6D).
HSPG2 and laminin subunit alpha-5 (LAMA5), also strongly downregulated in cells with persistent CVB1
10796 infection, are components of human peri-islet basement membrane, which protects pancreatic islets
from immune cell infiltration and thereby from beta-cell killing (Korpos et al., 2013; Otonkoski et al., 2008).
Persistent Coxsackievirus B1 Infections Can Both Activate and Shut Down Host Antiviral
Immune Responses
Acute CVB infection in human pancreatic islets induces strong type III interferon (IFN) responses (Lind et al.,
2013; Ylipaasto et al., 2012). In the current study, interferon lambda-1 (IFNL1) secretion was observed from
PANC-1 cells with persistent CVB1 ATCC infection. Interestingly, no IFNL1 was detected in the secretomes
of cells persistently infected with CVB1 10796 or in the secretomes of non-infected control cells (Figure 7A).
RT-qPCR analyses supported these findings, showing IFNL1mRNA expression only during persistent CVB1
ATCC infection (Figures 7B and S1). Also in general, the activation of antiviral immune responses was clearly
observed in persistent CVB1 ATCC infection model, whereas these responses were downregulated in
persistent CVB1 10796 infection model when compared with non-infected PANC-1 cells. Based on IPA
analysis, 14 of the 26 downstream targets of IFNL1 that were quantified in the cell lysates were significantly
upregulated during persistent infection with ATCC strain of CVB1 (Figure 7C). In contrast, none of these
proteins was upregulated in the CVB1 10796 persistent infection model. Of the IFNL1 downstream target
proteins, 11 were significantly downregulated in the cells with persistent CVB1 10796 infection and addi-
tional nine IFNL1 downstream target proteins were undetectable in these cells, although they were
detected in the non-infected PANC-1 cells (Figure 7D). The expression of a cytosolic viral RNA receptor
interferon-induced helicase C domain-containing protein 1 (IFIH1) was studied further using in situ hybrid-
ization. The data from two different time points, the latter one 72 days before the proteomics sample
collection, confirmed the high IFIH1 expression in samples from CVB1 ATCC persistent infection and
low expression or absence of IFIH1 in the CVB1 10796 persistent infection model and the non-infected con-
trol cells (Figure 7E). Also, other proteins associated with antiviral immune responses were significantly up-
regulated in cells with persistent CVB1 ATCC infection, whereas downregulated or undetected in cells with
persistent CVB1 10796 infection, including immunoproteasome component PSMB8, Endoplasmic reticu-
lum aminopeptidase 2 (ERAP2) involved in peptide trimming, tapasin (TAPBP) involved in peptide loading
on major histocompatibility complex class I, and human leukocyte antigen-C (HLA-C) (Table S2). Finally,
persistent CVB1 ATCC infection also upregulated the secretion of several proteins involved in antiviral im-
mune responses, including interleukin-18 (IL-18), and ubiquitin-like protein ISG15, whereas their secretion
from cells with persistent CVB1 10796 infection was lower than that from the non-infected cells (Table S3).
DISCUSSION
In the current study, two persistent CVB1 infectionmodels were established in human PANC-1 cell line, and
the infection-associated changes in the cells were characterized using proteomics approaches. Both intra-
cellular proteome and secretome were profiled to understand the infection-induced changes in cell func-
tion and intercellular communication. To understand the range of responses that can be triggered by
persistent CVB1 infections, the models were established using two CVB1 strains with clearly different abil-
ities to induce innate immune responses based on our previous studies (immunogenic ATCC strain and less
immunogenic 10796 strain) (Hamalainen et al., 2014). Although only a small proportion of the cells in both
persistent infection models were virus-positive based on IHC staining of the viral VP1 protein, broad
changes in protein expression and secretion were observed in both persistent infection models.
Carrier-state persistent infections are characterized by high titers of virus produced by a small number of
infected cells (Alidjinou et al., 2017; Pinkert et al., 2011). Several changes observed in the current persistent
CVB1 infection models support the presence of carrier-state persistence in the CVB1-infected PANC-1
cells. Studies on acute CVB infections have revealed multiple means by which CVBs modify the host cell
functions for improved viral replication (Ilnytska et al., 2013; Albulescu et al., 2015; Lee et al., 2017). In
the current study, several changes, which are likely beneficial for viral replication, were observed in both
persistent infection models. Active replication of the virus was also confirmed in both persistent infection
models by the detection of infective viral particles, viral VP1 protein, and viral genome as well as theiScience 19, 340–357, September 27, 2019 349
Figure 7. Antiviral Immune Responses during Persistent CVB1 Infections
(A) Changes in IFNL1 secretion from PANC-1 cells. For each sample, median intensity of three technical replicates is
shown. ND, not detected.
(B) IFNL1 mRNA expression in PANC-1 cells. The measurements were performed for the three biological replicates from
each condition. Primer sequences are presented in Table S7.
(C-D) Differentially expressed IFNL1 downstream target proteins in cells with persistent (C) CVB1 ATCC and (D) CVB1
10796 infection based on IPA analysis. Red, significantly upregulated; blue, significantly downregulated; white node with
red lines, detected only in the cells with persistent CVB1 ATCC infection; white node with blue lines, not detected in the
cells with persistent CVB1 10796 infection.
(E) IFIH1 expression in PANC-1 cells based on in situ hybridization. TP1, 102 days post-infection; TP2, 228 days post-
infection. Scale bar, 50 mm. In each bright-field image, fluorescent channel from the bright-field image is condensed into
corner.
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detection of viral proteins in cell lysates and cell culture supernatants in the proteomic analyses. After viral
replication, the infectious cycle of CVBs is usually completed via lytic release of mature virions from the in-
fected cells, followed by the infection of ‘‘naive’’ cells via their CVB receptor CXADR (Bergelson et al., 1997).
The lack of extensive cell lysis and the low number of virus-positive cells in carrier-state persistent infections
can be partly explained by the downregulation of the CVB receptor CXADR observed in both persistent
CVB1 infection models in the current study and in earlier models of carrier-state CVB persistency (Alidjinou
et al., 2017; Pinkert et al., 2011). CVBs can also bind to another receptor DAF (CD55) on cell surface, but
cannot undergo uncoating using that receptor (Bergelson and Coyne, 2013). Here, the expression of
DAF was not detected in the cell lysates and was detected only in the cell culture supernatants of the
non-infected PANC-1 cells. Furthermore, it is possible that the virus adapts to use other cellular receptors,
as new receptors for enteroviruses are still being discovered (Zhao et al., 2019). Pathway analysis of the cur-
rent proteomics data also revealed broader downregulation of proteins potentially involved in virus entry in
both persistent CVB1 infection models, which could further limit the spreading of the virus. Previously it has
been shown that CVBs may also spread directly from cell to cell via cellular protrusions (Paloheimo et al.,
2011). Finally, microvesicles expressing autophagosome markers, in particular LC3, have recently been re-
ported as a non-lytic means for the transmission of CVBs (Robinson et al., 2014; Sin et al., 2017). Downre-
gulation of LC3 B in the cell culture supernatants of both persistent infection models (Table S3) could be
associated with additional limitations in viral spreading via microvesicles during CVB1 persistency.
CVB proteins 2B, 2BC, and 3A have been shown to target the Golgi complex of the infected cell and to
disrupt protein trafficking through it (Campanella et al., 2004; Cornell et al., 2006; de Jong et al., 2006;
van Kuppeveld et al., 1997). Accordingly, acute CVB infections have been shown to modulate the secre-
tory pathway of the infected cells (Cornell et al., 2006; de Jong et al., 2006), including pancreatic
beta-cells (M.F.-T., unpublished data). CVB protein 2B can form pores in the ER and Golgi membranes
resulting in Ca2+ and H+ release from these intracellular stores (van Kuppeveld et al., 1997; Campanella
et al., 2004; de Jong et al., 2006). Acute infection of HeLa cells with CVB3 resulted in complete destruc-
tion of the Golgi complex, which was also observed after transfecting the cells with CVB3 3A protein
alone (Cornell et al., 2006). In the current study, persistent CVB1 infections were associated with broad
downregulation of proteins likely secreted via the classical secretory pathway in the cell culture superna-
tants of PANC-1 cells. In particular, proteins of the regulated secretory pathway were strongly downre-
gulated in the secretomes of PANC-1 cells with persistent CVB1 infection. Maintenance of the Ca2+ and
pH homeostasis in the ER and Golgi is important for many of these proteins, including CPE and the gra-
nin family members. Ca2+ and pH regulate the processing of pro-CPE and the activity of CPE, and Ca2+
and pH-dependent aggregation of CPE and granins has been proposed to act as a sorting mechanism
directing these proteins to the regulated secretory pathway (Chanat and Huttner, 1991; Ji et al., 2017;
Song and Fricker, 1995). Interestingly, although CPE protein was significantly downregulated in the
cell culture supernatants of the persistent CVB1 10796 infection model, significant upregulation of
CPE mRNA was observed in the cells in this model, indicating infection-associated defects in the
secretion of this protein. The possible infection-associated disruption of Ca2+ and pH homeostasis
in the ER and Golgi might have affected the sorting of CPE to the regulated secretory pathway, and/or
the potential virus-induced destruction of the Golgi complex could have inhibited its trafficking through
the regulated secretory pathway. Even if CPE was correctly addressed to the regulated secretory
pathway, virus-induced alterations in pH and Ca2+ levels are likely to influence its enzymatic activity.
CPE is a crucial protein, for example, for insulin maturation, and reduced CPE activity has been associ-
ated with elevated levels of proinsulin and reduced levels of biologically active insulin in mouse models
(Naggert et al., 1995).
ER stress is often induced by viral infections, including CVB infections (Colli et al., 2019; Zhang et al., 2010).
The type of these responses can vary depending on the cell type and the virus. The expression of one ER
stress protein, ER chaperone BiP (HSPA5) detected also in the current study, was shown to be induced by
acute CVB3 infection of HeLa and HL-1 cells (Zhang et al., 2010), whereas CVB5 infection of human beta-cell
line EndoC-bH1 did not change the expression of this protein (Colli et al., 2019). Instead, partial ER stress
via IRE1a phosphorylation was shown to be induced by CVB5 infection of EndoC-bH1 cells (Colli et al.,
2019). In the current study, the expression of HSPA5 was significantly downregulated during persistent
CVB1 10796 infection and slightly reduced during persistent CVB1 ATCC infection. Whether signs of partial
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In addition to the features common for the two persistent CVB1 infection models, several differences were
detected between these models. These differences could be associated with the distinct properties of the
ATCC and 10796 virus strains, random mutations accumulated in these viruses during persistency, or with
different kinetics of the infection-induced responses between the two persistent infection models.
The kinetics and magnitude of antiviral immune responses triggered by acute enterovirus infections
differ between distinct virus strains (Anagandula et al., 2014; Hamalainen et al., 2014; Ylipaasto et al.,
2012). Differences in the immunogenic properties of these viruses could also influence their ability to
persist in infected cells or tissues. Based on our earlier studies, acute infection of human peripheral
blood mononuclear cells (PBMCs) and dendritic cells with CVB1 ATCC strain clearly triggers a stronger
upregulation of antiviral immune responses than a similar infection with the CVB1 10796 strain (Hamalai-
nen et al., 2014). Furthermore, the infection of human pancreatic islets with CVB1 10796 strain only results
in moderate cytopathic effects (Anagandula et al., 2014). Still, an acute infection with the less immuno-
genic CVB1 10796 strain induces antiviral immune responses both in human pancreatic islets (Anagan-
dula et al., 2014) and in human PBMCs (Hamalainen et al., 2014; Lietzen et al., 2018). In the current study,
persistent infection with the ATCC strain of CVB1 was associated with IFNL1 secretion, upregulation of
several IFNL1 downstream target proteins, and upregulation of multiple other proteins involved in anti-
viral immune responses. These changes are in line with the antiviral immune responses triggered by
different CVBs in, for example, human pancreatic islets during acute infection (Ylipaasto et al., 2005,
2012; Lind et al., 2013, 2016; Nyalwidhe et al., 2017). In addition, immunofluorescence analyses of pancre-
atic tissue samples from organ donors with low-grade enterovirus infection and T1D have shown the
presence of antiviral EIF2AK2 in cells positive for enterovirus VP1 protein (Richardson et al., 2009,
2013). Interestingly, in this study persistent CVB1 10796 infection resulted in an apparent shutdown of
these host antiviral immune responses as indicated by the downregulation of numerous antiviral immune
response proteins when compared with non-infected controls. Furthermore, downregulated secretion of
immune response proteins, including pro-inflammatory cytokine IL-18, IFNL1, and ISG15, as observed in
persistent 10796 infection, would make the infected cells less visible for the immune system, likely delay-
ing their clearance.
The ability of a virus to circumvent host antiviral responses can provide important advantages, reducing
infection-induced stress in the cells and thereby allowing prolonged infection. In the current study, viral
proteins were more abundant in the cells and in the cell culture supernatants of persistent CVB1 10796
infection model when compared with the persistent CVB1 ATCC infection model, which could influence
more efficient blocking of host antiviral immune responses during persistent CVB1 10796 infection. Also
in an earlier study monitoring the growth kinetics of CVB1 strains in HeLa cells within a 48-h time frame,
CVB1 10796 was shown to replicate faster and produce more virus progeny than CVB1 ATCC strain (Hama-
lainen et al., 2014).
Mitochondrial antiviral-signaling protein (MAVS) is a central protein in host antiviral immune responses,
and signaling via MAVS, residing on mitochondrial or peroxisomal membranes, can induce type III IFN re-
sponses (Bender et al., 2015; Odendall et al., 2014). CVBs can use different strategies to suppress MAVS-
mediated host antiviral immune responses, and clearly reduced type I (Mukherjee et al., 2011; Feng et al.,
2014; Lind et al., 2016) and type III IFN responses (Lind et al., 2016) after acute CVB infections have been
observed in a few studies. CVB protease 2A can cleave MAVS resulting in suppressed type I and type III
IFN responses (Feng et al., 2014; Lind et al., 2016). According to our data MAVS was significantly downre-
gulated in the cells with persistent CVB1 10796 infection, whereas its expression in the CVB1 ATCC model
was only slightly, but not significantly, reduced when compared with the non-infected control cells (Table
S2). The clear downregulation of MAVS in the cells with persistent CVB1 10796 infection could be associ-
ated with, for example, higher expression of viral proteins in this model or with more efficient targeting of
MAVS by the CVB1 10796 protease 2A. Mitochondrial network fragmentation can also downregulate
MAVS-mediated antiviral signaling (Castanier et al., 2010). For example, cytomegalovirus inhibits MAVS-
mediated antiviral signaling by promoting fragmentation of the mitochondrial network (McCormick
et al., 2003), Dengue virus NS2B3 protease can attenuate cellular antiviral immunity by cleaving the mito-
chondrial fusion proteins MFN1 and MFN2 (Yu et al., 2015), and hepatitis C virus can induce mitochondrial
fragmentation by stimulating the dynamin-related protein 1 (DRP1) involved in mitochondrial fission (Kim
et al., 2014). Fragmented mitochondrial network has also been observed in murine cardiomyocytes during
acute CVB3 infection (Sin et al., 2017), and in the current study over 40% of the cells in CVB1 10796352 iScience 19, 340–357, September 27, 2019
persistent infection model had fragmented mitochondrial network. Based on these results, persistent
infection with 10796 strain of CVB1 is likely attenuating MAVS-mediated antiviral signaling more efficiently
than persistent infection with the ATCC strain of CVB1. However, other regulatory mechanisms are also
probably required to reach the broad downregulation of antiviral immune responses when compared
with the non-infected control cells.
Some of the strongest changes observed in the current persistent infection models involved proteins that
also have a role in pancreatic beta-cell function, differentiation, growth, and survival. Low-grade entero-
virus infections in human pancreatic islets have been associated with T1D in multiple studies (Yoon et al.,
1979; Richardson et al., 2009, 2013; Krogvold et al., 2015). Persistent CVB4 infection in PANC-1 cells has
been shown to result in the downregulation of PDX1, a transcription factor important for the develop-
ment and function of pancreatic beta-cells (Sane et al., 2013), and in the dysregulation of a set of
microRNAs with many of them potentially targeting T1D risk genes (Engelmann et al., 2017). In this study,
both persistent CVB1 infections resulted in strong downregulation of the key players of the regulated
secretory pathway, which in beta-cells is also responsible for insulin processing and secretion. This is
in line with an earlier study showing lower levels of insulin in beta-cells positive for the enterovirus
VP1 protein in pancreatic tissue samples from organ donors with T1D (Richardson et al., 2013). Strong
opposite changes induced by the two persistent CVB1 infection models were observed in the expression
of three proteins associated with pancreatic beta-cell differentiation, growth, and survival: ALDH1A3
(Cinti et al., 2016; Kim-Muller et al., 2016), SPARC (Ryall et al., 2014) and SUSD2 (Ramond et al., 2017).
In addition, persistent CVB1 10796 infection of PANC-1 cells resulted in significantly reduced expression
of two human peri-islet basement membrane proteins, HSPG2 and LAMA5 (Korpos et al., 2013; Oton-
koski et al., 2008), and also the secretion of HSPG2 was strongly downregulated in this persistent infec-
tion model. The reduced expression and secretion of peri-islet basement membrane components could
shift the balance between membrane destruction and repair, making pancreatic islets more susceptible
to leukocyte infiltration and beta-cell killing during enterovirus infection. Finally, increased secretion of
CSF1 was observed in both persistent infection models. CSF1 and its receptor (CSF1R) play essential
roles in the development of monocytes and in macrophage proliferation (Chitu and Stanley, 2006).
Increased expression of CSF1 has been reported in patients with myocarditis, and in a mouse model
of CVB3-induced myocarditis suppression of the CSF1 was shown to reduce the inflammatory outcome
and decrease the levels of infiltrating leukocytes (Meyer et al., 2018). Moreover, depletion of pancreatic
islet-resident macrophages by monoclonal autoantibody against CSF1R reduced the development of
autoimmune diabetes in NOD mice, indicating the importance of these cells in the disease pathogenesis
(Carrero et al., 2017).
Very recently, a study by Nekoua et al. described the establishment of persistent CVB4 infection in a
beta-cell-like cell line 1.1B4 and showed that the cells with persistent CVB4 infection are targets of natural
killer cell-mediated lysis (Nekoua et al., 2019). Still, the expression of insulin mRNA was not detected in
these cells. Future studies are needed to understand the benefits of this persistent infection model in
studying the potential outcomes of persistent CVB infections in human pancreas.
The current study provides a broad characterization of the changes induced by persistent CVB1 infection in
a human pancreatic ductal-like cell line. The parallel analysis of two distinct persistent infection models uti-
lizing CVB1 strains with different immunogenic properties is an important step towards understanding the
potential heterogeneity of the virus-cell interactions, which regulate the development of viral persistency
and its effects on the cell. Some of the changes observed in the current study are similar to the responses
triggered by acute enterovirus infections in human pancreatic islets, but importantly, our results also show
strong contrasting changes between the two persistent infection models not reported with acute entero-
virus infections. Further studies on persistent CVB infections are required to better understand the origins
of these differences. Finally, in the light of recent, but still very limited, data on the presence of CVBs also
outside pancreatic islets (Busse et al., 2017), we speculate that pancreatic ductal cells could also act as sites
for enterovirus persistence enabling from time to time spreading of the virus into the beta-cells. Larger
studies evaluating systematically the presence of these viruses in the endocrine and exocrine pancreas
are needed to further test this hypothesis. Overall, the current study covers novel information on persistent
CVB infection-induced changes in protein expression and secretion in a human pancreatic ductal-like cell
line and thereby provides new ideas for studying the pathogenic mechanisms of persistent enterovirus in-
fections in human pancreas tissue samples.iScience 19, 340–357, September 27, 2019 353
Limitations of the Study
Persistent CBV infection models established in human pancreatic cell lines are valuable tools to study the
potential outcomes of chronic CVB infections in human pancreas. One of the limitations of the current study
is the use of PANC-1 cell line instead of an insulin-producing human beta-cell line as a model system.
Despite the increasing amounts of evidence on connections between enterovirus infections and the devel-
opment of T1D, persistent CVB infection models have, to our knowledge, not yet been published in an in-
sulin-producing beta-cell line. Such studies would bring important insights into host-virus interplay during
prolonged CVB infection of pancreatic beta-cells. On the other hand, further mechanistic and functional
studies utilizing the existing persistent infection models would already bring deeper understanding on
the infection-induced responses observed in the current study. Finally, additional studies are needed for
comprehensive mapping of mutations in viral genomes acquired during persistency, and to understand
whether certain changes in viral genome are required for the formation of carrier-state persistent infections.METHODS
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The raw mass spectrometry data have been deposited to the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE partner repository (Vizcaı´no et al., 2012) with the
dataset identifiers PXD012153 and PXD012154.SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.07.040.ACKNOWLEDGMENTS
Wewish to thankProfessorDidierHober (University of Lille, Lille, France) for his valuablehelpwith thepersistent
infection models. Eini Eskola, Anne Karjalainen, Mervi Keka¨la¨inen, Tanja Kuusela, Maria Ovaskainen, Eveliina
Paloma¨ki, and Eeva Tolvanen (Faculty of Medicine and Health Technology, Tampere University) are acknowl-
edged for their technical support. University of Turku Virology laboratory led by Professor Ilkka Julkunen is
acknowledged for their help and facilities for proteomics sample preparation. Sarita Heinonen (Turku Biosci-
ence Center, University of Turku) is acknowledged for the technical assistance. The LC-MS/MS analyses pre-
sented in this workwere performedat the ProteomicsCore Facility of the TurkuBioscienceCenter that belongs
to Biocenter Finland infrastructure network. Themicroscopy experimentswereperformedat Tampere Imaging
Facility, BioMediTech, Faculty of Medicine and Health Technology, Tampere University.
This work was financially supported by the Academy of Finland decisions no. 287423, 288671, 292482,
292335, 294337, 319280, and 314444; Sigrid Juse´lius Foundation; Juvenile Diabetes Research Foundation
Ltd (JDRF); Finnish Diabetes Research Foundation; Turku University Foundation; Maud Kuistila Foundation;
and Reino Lahtikari Foundation. The project has also received funding from the InnovativeMedicines Initia-
tive 2 Joint Undertaking under grant agreement No 115797 (INNODIA). This Joint Undertaking receives
support from the Union’s Horizon 2020 research and innovation program and ‘‘EFPIA,’’ ‘‘JDRF,’’ and
‘‘The Leona M. and Harry B. Helmsley Charitable Trust. Studies at Karolinska Institutet were supported
by grants to M.F.-T from Karolinska Institutet including the Strategic Research Program in Diabetes, the
Swedish Research Council, and a grant from the Swedish Child Diabetes Foundation.AUTHOR CONTRIBUTIONS
N.L. and K.H. designed the proteomics experiments, prepared the proteomics samples, performed the
mass spectrometry experiments, and processed and analyzed the proteomics data. A.H. and A.-B.S.-K. es-
tablished the persistent infection model, and A.H. cultured the cells and provided the samples. T.B.,
M.A.M., and M.F.-T. performed the Taqman analyses. J.E.L. was responsible for the IHC stainings and
analyzed the samples. A.H. and A.-B.S.-K. performed the mitochondrial imaging experiments. E.D. helped
with the mitochondrial imaging experiments. S.O. performed the virus RT-PCR analyses. N.L., K.H., and
T.B. performed the western blot experiments. A.H. performed the cell viability analyses. N.L., K.H., and
A.H. wrote the paper with the help of T.B. A.-B.S.-K. critically revised the manuscript. R.L. and H.H. initiated354 iScience 19, 340–357, September 27, 2019
and supervised the study and critically revised the manuscript. All authors have contributed to the final
version of the manuscript.
DECLARATION OF INTERESTS
H.H. is a shareholder and chairman of the board of Vactech Ltd (http://www.vactech.fi/en/), which develops
vaccines against picornaviruses.
Received: April 4, 2019
Revised: July 8, 2019
Accepted: July 25, 2019
Published: September 27, 2019REFERENCES
Albulescu, L., Wubbolts, R., van Kuppeveld, F.J.,
and Strating, J.R. (2015). Cholesterol shuttling is
important for RNA replication of coxsackievirus
B3 and encephalomyocarditis virus. Cell.
Microbiol. 17, 1144–1156.
Alidjinou, E.K., Engelmann, I., Bossu, J., Villenet,
C., Figeac, M., Romond, M.B., Sane, F., and
Hober, D. (2017). Persistence of Coxsackievirus
B4 in pancreatic ductal-like cells results in cellular
and viral changes. Virulence 8, 1229–1244.
Anagandula, M., Richardson, S.J., Oberste, M.S.,
Sioofy-Khojine, A.-B., Hyo¨ty, H., Morgan, N.G.,
Korsgren, O., and Frisk, G. (2014). Infection of
human islets of langerhans with two strains of
coxsackie B virus serotype 1: Assessment of virus
replication, degree of cell death and induction of
genes involved in the innate immunity pathway.
J. Med. Virol. 86, 1402–1411.
Andreu, Z., and Ya´n˜ez-Mo´, M. (2014).
Tetraspanins in extracellular vesicle formation
and function. Front. Immunol. 5, 442.
Bartolomucci, A., Possenti, R., Mahata, S.K.,
Fischer-Colbrie, R., Loh, Y.P., and Salton, S.R.J.
(2011). The extended granin family: structure,
function, and biomedical implications. Endocr.
Rev. 32, 755–797.
Belov, G.A., Evstafieva, A.G., Rubtsov, Y.P.,
Mikitas, O.V., Vartapetian, A.B., and Agol, V.I.
(2000). Early alteration of nucleocytoplasmic
traffic induced by some RNA viruses. Virology
275, 244–248.
Bender, S., Reuter, A., Eberle, F., Einhorn, E.,
Binder, M., and Bartenschlager, R. (2015).
Activation of type I and III interferon response by
mitochondrial and peroxisomal MAVS and
inhibition by hepatitis C virus. PLoS Pathog. 11,
e1005264.
Bergelson, J.M., Cunningham, J.A., Droguett, G.,
Kurt-Jones, E.A., Krithivas, A., Hong, J.S., Horwitz,
M.S., Crowell, R.L., and Finberg, R.W. (1997).
Isolation of a common receptor for Coxsackie B
viruses and adenoviruses 2 and 5. Science 275,
1320–1323.
Bergelson, J.M., and Coyne, C.B. (2013).
Picornavirus entry. In Viral Entry into Host Cells.
Advances in Experimental Medicine and Biology,
790, S. Po¨hlmann and G. Simmons, eds., Viral
Entry into Host Cells. Advances in Experimental
Medicine and Biology (Springer), pp. 24–41.Borman, A.M., Kirchweger, R., Ziegler, E.,
Rhoads, R.E., Skern, T., and Kean, K.M. (1997).
elF4G and its proteolytic cleavage products:
effect on initiation of protein synthesis from
capped, uncapped, and IRES-containing mRNAs.
RNA 3, 186–196.
Busse, N., Paroni, F., Richardson, S.J., Laiho, J.E.,
Oikarinen, M., Frisk, G., Hyo¨ty, H., de Koning, E.,
Morgan, N.G., and Maedler, K. (2017). Detection
and localization of viral infection in the pancreas
of patients with type 1 diabetes using short
fluorescently-labelled oligonucleotide probes.
Oncotarget 8, 12620–12636.
Campanella, M., de Jong, A.S., Lanke, K.W.H.,
Melchers, W.J.G., Willems, P.H.G.M., Pinton, P.,
Rizzuto, R., and van Kuppeveld, F.J.M. (2004). The
coxsackievirus 2B protein suppresses apoptotic
host cell responses by manipulating intracellular
Ca2+ homeostasis. J. Biol. Chem. 279, 18440–
18450.
Carrero, J.A., McCarthy, D.P., Ferris, S.T., Wan, X.,
Hu, H., Zinselmeyer, B.H., Vomund, A.N., and
Unanue, E.R. (2017). Resident macrophages of
pancreatic islets have a seminal role in the
initiation of autoimmune diabetes of NOD mice.
Proc. Natl. Acad. Sci. U S A 114, E10418–E10427.
Castanier, C., Garcin, D., Vazquez, A., and
Arnoult, D. (2010). Mitochondrial dynamics
regulate the RIG-I-like receptor antiviral pathway.
EMBO Rep. 11, 133–138.
Chanat, E., and Huttner, W.B. (1991). Milieu-
induced, selective aggregation of regulated
secretory proteins in the trans-Golgi network.
J. Cell Biol. 115, 1505–1519.
Chapman, N.M., and Kim, K.S. (2008). Persistent
coxsackievirus infection: enterovirus persistence
in chronic myocarditis and dilated
cardiomyopathy. Curr. Top. Microbiol. Immunol.
323, 275–292.
Chehadeh, W., Kerr-Conte, J., Pattou, F., Alm, G.,
Lefebvre, J., Wattre´, P., and Hober, D. (2000).
Persistent infection of human pancreatic islets by
coxsackievirus B is associated with alpha
interferon synthesis in beta cells. J. Virol. 74,
10153–10164.
Chitu, V., and Stanley, E.R. (2006). Colony-
stimulating factor-1 in immunity and
inflammation. Curr. Opin. Immunol. 18, 39–48.
Cinti, F., Bouchi, R., Kim-Muller, J.Y., Ohmura, Y.,
Sandoval, P.R., Masini, M., Marselli, L., Suleiman,iM., Ratner, L.E., Marchetti, P., et al. (2016).
Evidence of b-cell dedifferentiation in human
type 2 diabetes. J. Clin. Endocrinol. Metab. 101,
1044–1054.
Colli, M.L., Paula, F.M., Marselli, L., Marchetti, P.,
Roivainen, M., Eizirik, D.L., and Op de beeck, A.
(2019). Coxsackievirus B tailors the unfolded
protein response to favour viral amplification in
pancreatic b cells. J. Innate Immun. 11, 375–390.
Cornell, C.T., Kiosses, W.B., Harkins, S., and
Whitton, J.L. (2006). Inhibition of protein
trafficking by coxsackievirus B3: multiple viral
proteins target a single organelle. J. Virol. 80,
6637–6647.
Courel, M., Soler-Jover, A., Rodriguez-Flores,
J.L., Mahata, S.K., Elias, S., Montero-Hadjadje,
M., Anouar, Y., Giuly, R.J., O’Connor, D.T., and
Taupenot, L. (2010). Pro-hormone secretogranin
II regulates dense core secretory granule
biogenesis in catecholaminergic cells. J. Biol.
Chem. 285, 10030–10043.
Eipper, B.A., Milgram, S.L., Husten, E.J., Yun,
H.Y., and Mains, R.E. (1993). Peptidylglycine
alpha-amidating monooxygenase: a
multifunctional protein with catalytic, processing,
and routing domains. Protein Sci. A Publ. Protein
Soc. 2, 489–497.
Engelmann, I., Alidjinou, E.K., Bertin, A., Bossu, J.,
Villenet, C., Figeac, M., Sane, F., and Hober, D.
(2017). Persistent coxsackievirus B4 infection
induces microRNA dysregulation in human
pancreatic cells. Cell. Mol. Life Sci. 74, 3851–3861.
Feng, Q., Langereis, M.A., Lork, M., Nguyen, M.,
Hato, S.V., Lanke, K., Emdad, L., Bhoopathi, P.,
Fisher, P.B., Lloyd, R.E., et al. (2014). Enterovirus
2Apro targets MDA5 and MAVS in infected cells.
J. Virol. 88, 3369–3378.
Frisk, G. (2001). Mechanisms of chronic
enteroviral persistence in tissue. Curr. Opin.
Infect. Dis. 14, 251–256.
Gustin, K.E., and Sarnow, P. (2001). Effects of
poliovirus infection on nucleo-cytoplasmic
trafficking and nuclear pore complex
composition. EMBO J. 20, 240–249.
Hamalainen, S., Nurminen, N., Ahlfors, H.,
Oikarinen, S., Sioofy-Khojine, A.B., Frisk, G.,
Oberste, M.S., Lahesmaa, R., Pesu,M., and Hyoty,
H. (2014). Coxsackievirus B1 reveals strain specific
differences in plasmacytoid dendritic cellScience 19, 340–357, September 27, 2019 355
mediated immunogenicity. J. Med. Virol. 86,
1412–1420.
Hosaka, M., Suda, M., Sakai, Y., Izumi, T.,
Watanabe, T., and Takeuchi, T. (2004).
Secretogranin III binds to cholesterol in the
secretory granule membrane as an adapter for
chromogranin A. J. Biol. Chem. 279, 3627–3634.
Huh, Y.H., Jeon, S.H., and Yoo, S.H. (2003).
Chromogranin B-induced secretory granule
biogenesis: comparison with the similar role of
chromogranin A. J. Biol. Chem. 278, 40581–
40589.
Hyoty, H. (2016). Viruses in type 1 diabetes.
Pediatr. Diabetes 17 (Suppl 2 ), 56–64.
Ifie, E., Russell, M.A., Dhayal, S., Leete, P.,
Sebastiani, G., Nigi, L., Dotta, F., Marjoma¨ki, V.,
Eizirik, D.L., Morgan, N.G., et al. (2018).
Unexpected subcellular distribution of a specific
isoform of the Coxsackie and adenovirus
receptor, CAR-SIV, in human pancreatic beta
cells. Diabetologia 61, 2344–2355.
Ilnytska, O., Santiana, M., Hsu, N.Y., Du, W.L.,
Chen, Y.H., Viktorova, E.G., Belov, G., Brinker, A.,
Storch, J., Moore, C., et al. (2013). Enteroviruses
harness the cellular endocytic machinery to
remodel the host cell cholesterol landscape for
effective viral replication. Cell Host Microbe 14,
281–293.
Ji, L., Wu, H.-T., Qin, X.-Y., and Lan, R. (2017).
Dissecting carboxypeptidase E: properties,
functions and pathophysiological roles in
disease. Endocr. Connect. 6, R18–R38.
de Jong, A.S., Visch, H.-J., de Mattia, F., van
Dommelen, M.M., Swarts, H.G., Luyten, T.,
Callewaert, G., Melchers, W.J., Willems, P.H., and
van Kuppeveld, F.J. (2006). The coxsackievirus 2B
protein increases efflux of ions from the
endoplasmic reticulum and Golgi, thereby
inhibiting protein trafficking through the Golgi.
J. Biol. Chem. 281, 14144–14150.
Kim-Muller, J.Y., Fan, J., Kim, Y.J.R., Lee, S.-A.,
Ishida, E., Blaner, W.S., and Accili, D. (2016).
Aldehyde dehydrogenase 1a3 defines a subset of
failing pancreatic b cells in diabetic mice. Nat.
Commun. 7, 12631.
Kim, K.S., Chapman, N.M., and Tracy, S. (2008).
Replication of coxsackievirus B3 in primary cell
cultures generates novel viral genome deletions.
J. Virol. 82, 2033–2037.
Kim, S.-J., Syed, G.H., Khan, M., Chiu, W.-W.,
Sohail, M.A., Gish, R.G., and Siddiqui, A. (2014).
Hepatitis C virus triggers mitochondrial fission
and attenuates apoptosis to promote viral
persistence. Proc. Natl. Acad. Sci. U S A 111,
6413–6418.
Knockenhauer, K.E., and Schwartz, T.U. (2016).
The nuclear pore complex as a flexible and
dynamic gate. Cell 164, 1162–1171.
Korpos, E´., Kadri, N., Kappelhoff, R., Wegner, J.,
Overall, C.M., Weber, E., Holmberg, D., Cardell,
S., and Sorokin, L. (2013). The peri-islet basement
membrane, a barrier to infiltrating leukocytes in
type 1 diabetes in mouse and human. Diabetes
62, 531–542.
Krogvold, L., Edwin, B., Buanes, T., Frisk, G.,
Skog, O., Anagandula, M., Korsgren, O., Undlien,356 iScience 19, 340–357, September 27, 2019D., Eike, M.C., Richardson, S.J., et al. (2015).
Detection of a low-grade enteroviral infection in
the islets of langerhans of living patients newly
diagnosed with type 1 diabetes. Diabetes 64,
1682–1687.
van Kuppeveld, F.J., Hoenderop, J.G., Smeets,
R.L., Willems, P.H., Dijkman, H.B., Galama, J.M.,
and Melchers, W.J. (1997). Coxsackievirus protein
2B modifies endoplasmic reticulum membrane
and plasma membrane permeability and
facilitates virus release. EMBO J. 16, 3519–3532.
Laitinen, O.H., Honkanen, H., Pakkanen, O.,
Oikarinen, S., Hankaniemi, M.M., Huhtala, H.,
Ruokoranta, T., Lecouturier, V., Andre, P., Harju,
R., et al. (2014). Coxsackievirus B1 is associated
with induction of beta-cell autoimmunity that
portends type 1 diabetes. Diabetes 63, 446–455.
Laitinen, O.H., Svedin, E., Kapell, S., Nurminen,
A., Hyto¨nen, V.P., and Flodstro¨m-Tullberg, M.
(2016). Enteroviral proteases: structure, host
interactions and pathogenicity. Rev. Med. Virol.
26, 251–267.
Lee, K.-M., Chen, C.-J., and Shih, S.-R. (2017).
Regulation mechanisms of viral IRES-driven
translation. Trends Microbiol. 25, 546–561.
Lietzen, N., An, L.T.T., Jaakkola, M.K., Kallionpa¨a¨,
H., Oikarinen, S., Mykka¨nen, J., Knip, M., Veijola,
R., Ilonen, J., Toppari, J., et al. (2018). Enterovirus-
associated changes in blood transcriptomic
profiles of children with genetic susceptibility to
type 1 diabetes. Diabetologia 61, 381–388.
Lind, K., Richardson, S.J., Leete, P., Morgan, N.G.,
Korsgren, O., and Flodstro¨m-Tullberg, M. (2013).
Induction of an antiviral state and attenuated
coxsackievirus replication in type III interferon-
treated primary human pancreatic islets. J. Virol.
87, 7646–7654.
Lind, K., Svedin, E., Domsgen, E., Kapell, S.,
Laitinen, O.H., Moll, M., and Flodstro¨m-Tullberg,
M. (2016). Coxsackievirus counters the host innate
immune response by blocking type III interferon
expression. J. Gen. Virol. 97, 1368–1380.
Massilamany, C., Gangaplara, A., and Reddy, J.
(2014). Intricacies of cardiac damage in
coxsackievirus B3 infection: implications for
therapy. Int. J. Cardiol. 177, 330–339.
McCormick, A.L., Smith, V.L., Chow, D., and
Mocarski, E.S. (2003). Disruption of mitochondrial
networks by the human cytomegalovirus UL37
gene product viral mitochondrion-localized
inhibitor of apoptosis. J. Virol. 77, 631–641.
Meyer, I.S., Goetzke, C.C., Kespohl, M., Sauter,
M., Heuser, A., Eckstein, V., Vornlocher, H.-P.,
Anderson, D.G., Haas, J., Meder, B., et al. (2018).
Silencing the CSF-1 axis using nanoparticle
encapsulated sirna mitigates viral and
autoimmune myocarditis. Front. Immunol. 9,
2303.
Mukherjee, A., Morosky, S.A., Delorme-Axford,
E., Dybdahl-Sissoko, N., Oberste, M.S., Wang, T.,
and Coyne, C.B. (2011). The coxsackievirus B 3C
protease cleaves MAVS and TRIF to attenuate
host type I interferon and apoptotic signaling.
PLoS Pathog. 7, e1001311.
Naggert, J.K., Fricker, L.D., Varlamov, O., Nishina,
P.M., Rouille, Y., Steiner, D.F., Carroll, R.J.,
Paigen, B.J., and Leiter, E.H. (1995).Hyperproinsulinaemia in obese fat/fat mice
associated with a carboxypeptidase E mutation
which reduces enzyme activity. Nat. Genet. 10,
135–142.
Nekoua, M.P., Bertin, A., Sane, F., Alidjinou, E.K.,
Lobert, D., Trauet, J., Hober, C., Engelmann, I.,
Moutairou, K., Yessoufou, A., et al. (2019).
Pancreatic beta cells persistently infected with
coxsackievirus B4 are targets of NK cell-mediated
cytolytic activity. Cell. Mol. Life Sci., In press.
https://doi.org/10.1007/s00018-019-03168-4.
Nishtala, K., Phong, T.Q., Steil, L., Sauter, M.,
Salazar, M.G., Kandolf, R., Kroemer, H.K., Felix,
S.B., Vo¨lker, U., Klingel, K., et al. (2011). Virus-
induced dilated cardiomyopathy is characterized
by increased levels of fibrotic extracellular matrix
proteins and reduced amounts of energy-
producing enzymes. Proteomics 11, 4310–4320.
Nurminen, N., Oikarinen, S., and Hyoty, H. (2012).
Virus infections as potential targets of preventive
treatments for type 1 diabetes. Rev. Diabet. Stud.
9, 260–271.
Nyalwidhe, J.O., Gallagher, G.R., Glenn, L.M.,
Morris, M.A., Vangala, P., Jurczyk, A., Bortell, R.,
Harlan, D.M., Wang, J.P., and Nadler, J.L. (2017).
Coxsackievirus-induced proteomic alterations in
primary human islets provide insights for the
etiology of diabetes. J. Endocr. Soc. 1, 1272–
1286.
Odendall, C., Dixit, E., Stavru, F., Bierne, H.,
Franz, K.M., Durbin, A.F., Boulant, S., Gehrke, L.,
Cossart, P., and Kagan, J.C. (2014). Diverse
intracellular pathogens activate type III interferon
expression from peroxisomes. Nat. Immunol. 15,
717–726.
Oikarinen, S., Tauriainen, S., Hober, D., Lucas, B.,
Vazeou, A., Sioofy-Khojine, A., Bozas, E., Muir, P.,
Honkanen, H., Ilonen, J., et al. (2014). Virus
antibody survey in different European
populations indicates risk association between
coxsackievirus B1 and type 1 diabetes. Diabetes
63, 655–662.
Oshima, M., Knoch, K.-P., Diedisheim, M.,
Petzold, A., Cattan, P., Bugliani, M., Marchetti, P.,
Choudhary, P., Huang, G.-C., Bornstein, S.R.,
et al. (2018). Virus-like infection induces human b
cell dedifferentiation. JCI Insight 3, 97732.
Otonkoski, T., Banerjee, M., Korsgren, O.,
Thornell, L.-E., and Virtanen, I. (2008). Unique
basement membrane structure of human
pancreatic islets: implications for beta-cell
growth and differentiation. Diabetes Obes.
Metab. 10 (Suppl 4 ), 119–127.
Paloheimo, O., Ihalainen, T.O., Tauriainen, S.,
Va¨lilehto, O., Kirjavainen, S., Niskanen, E.A.,
Laakkonen, J.P., Hyo¨ty, H., and Vihinen-Ranta, M.
(2011). Coxsackievirus B3-induced cellular
protrusions: structural characteristics and
functional competence. J. Virol. 85, 6714–6724.
Petersen, T.N., Brunak, S., von Heijne, G., and
Nielsen, H. (2011). SignalP 4.0: discriminating
signal peptides from transmembrane regions.
Nat. Methods 8, 785–786.
Pinkert, S., Klingel, K., Lindig, V., Dorner, A.,
Zeichhardt, H., Spiller, O.B., and Fechner, H.
(2011). Virus-host coevolution in a persistently
coxsackievirus B3-infected cardiomyocyte cell
line. J. Virol. 85, 13409–13419.
Richardson, S.J., Willcox, A., Bone, A.J., Foulis,
A.K., and Morgan, N.G. (2009). The prevalence of
enteroviral capsid protein vp1 immunostaining in
pancreatic islets in human type 1 diabetes.
Diabetologia 52, 1143–1151.
Ramond, C., Glaser, N., Berthault, C., Ameri, J.,
Kirkegaard, J.S., Hansson, M., Honore´, C., Semb,
H., and Scharfmann, R. (2017). Reconstructing
human pancreatic differentiation by mapping
specific cell populations during development.
Elife 6, e27564.
Richardson, S.J., Leete, P., Bone, A.J., Foulis,
A.K., and Morgan, N.G. (2013). Expression of the
enteroviral capsid protein VP1 in the islet cells of
patients with type 1 diabetes is associated with
induction of protein kinase R and downregulation
of Mcl-1. Diabetologia 56, 185–193.
Robinson, S.M., Tsueng, G., Sin, J., Mangale, V.,
Rahawi, S., McIntyre, L.L., Williams, W., Kha, N.,
Cruz, C., Hancock, B.M., et al. (2014).
Coxsackievirus B exits the host cell in shed
microvesicles displaying autophagosomal
markers. PLoS Pathog. 10, e1004045.
Ryall, C.L., Viloria, K., Lhaf, F., Walker, A.J., King,
A., Jones, P., Mackintosh, D., McNeice, R.,
Kocher, H., Flodstrom-Tullberg, M., et al. (2014).
Novel role for matricellular proteins in the
regulation of islet b cell survival: the effect of
SPARC on survival, proliferation, and signaling.
J. Biol. Chem. 289, 30614–30624.
Sane, F., Caloone, D., Gmyr, V., Engelmann, I.,
Belaich, S., Kerr-Conte, J., Pattou, F., Desailloud,
R., and Hober, D. (2013). Coxsackievirus B4 can
infect human pancreas ductal cells and persist in
ductal-like cell cultures which results in inhibition
of Pdx1 expression and disturbed formation of
islet-like cell aggregates. Cell. Mol. Life Sci. 70,
4169–4180.
Sean, P., Nguyen, J.H.C., and Semler, B.L. (2009).
Altered interactions between stem-loop IV within
the 5’ noncoding region of coxsackievirus RNAand poly(rC) binding protein 2: effects on IRES-
mediated translation and viral infectivity. Virology
389, 45–58.
Sin, J., McIntyre, L., Stotland, A., Feuer, R., and
Gottlieb, R.A. (2017). Coxsackievirus B escapes
the infected cell in ejected mitophagosomes.
J. Virol. 91, e01347–17.
Sioofy-Khojine, A.B., Lehtonen, J., Nurminen, N.,
Laitinen, O.H., Oikarinen, S., Huhtala, H.,
Pakkanen, O., Ruokoranta, T., Hankaniemi, M.M.,
Toppari, J., et al. (2018). Coxsackievirus B1
infections are associated with the initiation of
insulin-driven autoimmunity that progresses to
type 1 diabetes. Diabetologia 61, 1193–1202.
Song, L., and Fricker, L.D. (1995). Calcium- and
pH-dependent aggregation of carboxypeptidase
E. J. Biol. Chem. 270, 7963–7967.
Tapparel, C., Siegrist, F., Petty, T.J., and Kaiser, L.
(2013). Picornavirus and enterovirus diversity with
associated human diseases. Infect. Genet. Evol.
14, 282–293.
Tuthill, T.J., Groppelli, E., Hogle, J.M., and
Rowlands, D.J. (2010). Picornaviruses. Curr. Top.
Microbiol. Immunol. 343, 43–89.
Vizcaı´no, J.A., Coˆte´, R.G., Csordas, A., Dianes,
J.A., Fabregat, A., Foster, J.M., Griss, J., Alpi, E.,
Birim, M., Contell, J., et al. (2012). The Proteomics
Identifications (PRIDE) database and associated
tools: status in 2013. Nucleic Acids Res. 41,
D1063–D1069.
Wai, T., and Langer, T. (2016). Mitochondrial
dynamics and metabolic regulation. Trends
Endocrinol. Metab. 27, 105–117.
Xu, J., Nie, H., Zhang, X., Tian, Y., and Yu, B.
(2011). Down-regulated energy metabolism
genes associated with mitochondria oxidative
phosphorylation and fatty acid metabolism in
viral cardiomyopathymouse heart. Mol. Biol. Rep.
38, 4007–4013.iYlipaasto, P., Klingel, K., Lindberg, A.M.,
Otonkoski, T., Kandolf, R., Hovi, T., and
Roivainen, M. (2004). Enterovirus infection in
human pancreatic islet cells, islet tropism in vivo
and receptor involvement in cultured islet beta
cells. Diabetologia 47, 225–239.
Ylipaasto, P., Kutlu, B., Rasilainen, S., Rasschaert,
J., Salmela, K., Teerijoki, H., Korsgren, O.,
Lahesmaa, R., Hovi, T., Eizirik, D.L., et al. (2005).
Global profiling of coxsackievirus- and cytokine-
induced gene expression in human pancreatic
islets. Diabetologia 48, 1510–1522.
Ylipaasto, P., Smura, T., Gopalacharyulu, P.,
Paananen, A., Seppanen-Laakso, T., Kaijalainen,
S., Ahlfors, H., Korsgren, O., Lakey, J.R.,
Lahesmaa, R., et al. (2012). Enterovirus-induced
gene expression profile is critical for human
pancreatic islet destruction. Diabetologia 55,
3273–3283.
Yoon, J.W., Austin, M., Onodera, T., and Notkins,
A.L. (1979). Isolation of a virus from the pancreas
of a child with diabetic ketoacidosis. N. Engl. J.
Med. 300, 1173–1179.
Yu, C.-Y., Liang, J.-J., Li, J.-K., Lee, Y.-L., Chang,
B.-L., Su, C.-I., Huang, W.-J., Lai, M.M.C., and Lin,
Y.-L. (2015). Dengue virus impairs mitochondrial
fusion by cleaving mitofusins. PLoS Pathog. 11,
e1005350.
Zhang, H.M., Ye, X., Su, Y., Yuan, J., Liu, Z., Stein,
D.A., and Yang, D. (2010). Coxsackievirus B3
infection activates the unfolded protein response
and induces apoptosis through downregulation
of p58IPK and activation of CHOP and SREBP1.
J. Virol. 84, 8446–8459.
Zhao, X., Zhang, G., Liu, S., Chen, X., Peng, R.,
Dai, L., Qu, X., Li, S., Song, H., Gao, Z., et al.
(2019). Human neonatal fc receptor is the cellular
uncoating receptor for enterovirus B. Cell 177,
1553–1565.e16.Science 19, 340–357, September 27, 2019 357
ISCI, Volume 19Supplemental InformationCoxsackievirus B Persistence Modiﬁes
the Proteome and the Secretome
of Pancreatic Ductal Cells
Niina Lietzén, Karoliina Hirvonen, Anni Honkimaa, Tanja Buchacher, Jutta E. Laiho, Sami
Oikarinen, Magdalena A. Mazur, Malin Flodström-Tullberg, Eric Dufour, Amir-Babak
Sioofy-Khojine, Heikki Hyöty, and Riitta Lahesmaa
Figure S1 (related to Fig. 7). IFNL1 RT-qPCR for cells cultured in serum-containing medium.
A sample set including three biological repeats of persistently infected cells and non-infected cells in
serum-containing medium were collected at 279, 286 and 293 days post infection for innate immune
response analysis similarly as described in Materials and Methods-section, but the cells were lysed
and stored in RLT-lysis buffer prior to RNA extraction.
IFNL1 mRNA was quantified using the Taqman Gene expression assay (Applied Biosystems). In brief,
extracted RNA (RNeasy kit, Qiagen) was transcribed into cDNA using random hexamers, dNTP mix,
RNase inhibitor and 5x Buffer (Promega). PCR reaction was performed using TaqMan® Fast Advanced
Master Mix (Applied Biosystems) and human specific Gene expression assay  primer/probe set
(Applied Biosystems) to amplify and quantify human IFNL1 (Assay ID: Hs00601677_g1). Samples were
run on a QuantStudio5 (Applied Biosystems) Comparative Ct Fast program (20 sec of 95°C followed by
40 cycles of 1 sec 95°C, 20 sec 60°C). All reactions were performed in triplicate and gene expression of
the studied genes was normalized to the reference gene (GAPDH) and expressed as deltaCt.
Table S1 (related to Fig. 1). Evaluation of cell death.
Cell death was approximated by ToxiLight cell viability assay kit. Samples from the first two timepoints
used for proteomics analyses (#1 and #2) were analysed. The measurements were performed after
culturing the cells in FBS-free medium for two days. Minor (<10 %) cell death was detected at each
sample. CVB1 ATCC samples marked with an asterisk (*) are test samples in which the two days culture
in serum-free medium (#1) was compared with 5 days culture in serum-free medium (#2). No
significant difference was detected.
Sample Cell death percentage (n=3)
control #1 5.40 ± 0.14%
control #2 8.00 ± 0.53 %
CVB1 ATCC #1 3.52 ± 0.14  %
CVB1 ATCC #2 5.66 ± 0.34%
CVB1 10796 #1 1.31 ± 0.06  %
CVB1 10796 #2 2.02 ± 0.10 %
CVB1 ATCC #1 * 4.11 ± 0.31 %
CVB1 ATCC #2 * 4.27± 0.47 %
Table S6 (related to Fig. 3 and Fig. 5). Gene Ontology (cellular component) enrichment of the
differentially expressed proteins in (A) cell lysates and (B) secretome using DAVID tool. Only
significantly enriched categories (FDR < 0.05) are shown.
A
Upregulated in cells during persistent CVB1 ATCC infection
Term Count Fold Enrichment FDR
GO:0005737~cytoplasm 203 1.315252 1.90E-04
GO:0005829~cytosol 167 1.317985 0.008838
Upregulated in cells during persistent CVB1 CDC7 infection
Term Count Fold Enrichment FDR
GO:0005829~cytosol 169 1.358935 7.60E-04
GO:0005634~nucleus 182 1.330353 8.18E-04
Downregulated in cells during persistent CVB1 ATCC infection
Term Count Fold Enrichment FDR
GO:0016021~integral component of membrane 224 1.397357 4.47E-06
GO:0005753~mitochondrial proton-transporting ATP
synthase complex 14 5.059959 5.61E-05
GO:0005759~mitochondrial matrix 65 1.685573 0.015347
Downregulated in cells during persistent CVB1 10796 infection
Term Count Fold Enrichment FDR
GO:0005739~mitochondrion 366 1.407814 1.18E-14
GO:0005759~mitochondrial matrix 124 1.715361 9.74E-10
GO:0005743~mitochondrial inner membrane 159 1.567081 8.79E-09
GO:0016021~integral component of membrane 389 1.294519 1.84E-08
GO:0005765~lysosomal membrane 68 1.565463 0.021283
BTop 20 Gene Ontology classes enriched among the differentially expressed proteins in
secretome data
Term Count Fold Enrichment FDR
GO:0070062~extracellular exosome 623 2.779747149 2.54E-150
GO:0005829~cytosol 505 1.910671114 7.62E-53
GO:0005913~cell-cell adherens junction 127 4.93150288 2.76E-52
GO:0005925~focal adhesion 139 4.458780933 2.50E-51
GO:0016020~membrane 370 2.109391228 1.00E-45
GO:0005737~cytoplasm 617 1.481925561 7.19E-29
GO:0031012~extracellular matrix 87 3.686426964 4.62E-24
GO:0043202~lysosomal lumen 45 6.640055058 4.41E-23
GO:0022625~cytosolic large ribosomal subunit 38 7.008947006 3.97E-20
GO:0005840~ribosome 59 4.457814741 5.08E-20
GO:0005615~extracellular space 206 1.918128583 1.18E-17
GO:0005764~lysosome 60 3.329821121 1.67E-13
GO:0005654~nucleoplasm 332 1.495708443 3.23E-12
GO:0042470~melanosome 35 4.346350671 2.12E-10
GO:0005730~nucleolus 129 1.887934752 2.71E-09
GO:0005788~endoplasmic reticulum lumen 48 3.135581555 3.30E-09
GO:0048471~perinuclear region of cytoplasm 101 2.039895247 1.06E-08
GO:0030529~intracellular ribonucleoprotein complex 38 3.504473503 2.63E-08
GO:0005794~Golgi apparatus 126 1.831208695 4.17E-08
GO:0009986~cell surface 86 1.990110803 1.60E-06
Table S7 (related to Fig. 5 and Fig. 7). Reagents used for RT-qPCR.
Gene 1) 5' -PROBE- 3'
2) 5' -PRIMER 1- 3'
3) 5' -PRIMER 2 -3'
CHGB 1) Universal Probelibrary probe #79
2) 5’- ttctgaggagccggtgag -3’
3) 5’- gaactcgaaaacttggctgc -3’
CPE 1) Universal Probelibrary probe #3
2) 5’- gaaagtggcagttccttacagc -3’
3) 5’- ttttgaactggagtcattttctga  -3’
IFNL1 1) Universal Probelibrary probe #79
2) 5' - ggcctgtatccagcctca -3'
3) 5' - ctggaggcatctgtcacctt- 3'
SCG3 1) Universal Probelibrary probe #47
2) 5’- gagtggattggatcataaatttcaa -3’
3) 5’- atgaagtagcagaggttttacaaaaat -3’
TRANSPARENT METHODS
Establishment of persistent enterovirus infection in PANC-1 cells
Pancreatic ductal cells (PANC-1 cell line obtained from Professor Didier Hober’s laboratory, Lille,
France) were cultured in Dulbecco’s modified eagles media (DMEM) supplemented with 10 % v/v of
fetal bovine serum (FBS, Gibco) and 0.5 % v/v penicillin- streptomycin (Pen-Strep, Gibco). Persistent
infection was established using a protocol earlier published by Famara Sane and the colleagues (Sane
et al., 2013). PANC-1 cells were infected with CVB1 prototype strain obtained from ATCC (American
type culture collection, strain Conn-5) and with a wild type CVB1 strain (strain 10796), which was
obtained from Centers for Disease Control and Prevention (CDC) and isolated originally in Argentina
in 1983 (Hamalainen et al., 2014). Primary infection of PANC-1 cells was done using a low titer of the
virus leading to a strong cytopathic effect and extensive cell death. After 11 days post infection all
remaining living cells were detached from the plastic mechanically by scraping with cell scraper
(Greiner Bio-One) and transferred on fresh PANC-1 cells in a 6-well plate (Nunc). A strong cytopathic
effect was again seen soon after the cells were added on top of fresh cells, after which the remaining
living cells were maintained by washing the culture plates with Hank’s balanced salt solution (HBSS)
regularly. After the cells started to grow they were maintained by regular HBSS washes and passaged
once a week by using cell scraper. The presence of the virus in the persistent infection models was
verified by RT-qPCR method earlier described by Honkanen et al. (Honkanen et al., 2013), which
detects the viral RNA from culture supernatants. In addition, viral protein VP1 was detected from
cellular samples by IHC (see below). Plaque morphology of the virus was verified by standard plaque
titration assay on GMK cells. Resistance of persistently infected cells to coinfection with the parental
virus strain and CVB3 (obtained from ATCC) was carried out as described earlier (Alidjinou et al., 2017;
Pinkert et al., 2011).
Detection of viral protein by immunohistochemistry
The cells were harvested 362 days post infection by scraping and fixed in 10% formalin (Oy FF-
Chemicals Ab) for 24 h prior to dehydration and paraffin embedding. An automated immunostaining
was performed for the formalin-fixed paraffin-embedded (FFPE) cell samples using a commercially
available monoclonal antibody (clone 5-D8/1, Agilent Dako, product code M 7064), detecting
enterovirus capsid protein VP1, as previously described (Krogvold et al., 2015). Imaging was done using
an Olympus BX-60 microscope.
Sample collection for proteomics
Three biological repeats of persistently infected cells and non-infected control cells were collected
300-322 days post infection for proteomics analysis. The cells were cultured in serum-free DMEM
medium supplemented with antibiotics for four days prior to sample collection. Cells were collected
by scraping (Grainer-Bio cell scraper), pelleted by centrifugation for 2500 rpm, 10min (Heraeus Christ)
and frozen as dry cell pellets in -80 ˚C. Cell culture supernatants were also collected, cleared by
centrifugation (Heraeus Christ centrifuge, 2500 rpm, 10min) and stored at -80 °C. Cell viability in
proteomics samples was estimated two days prior to sample collection by ToxiLight™ Non-destructive
Cytotoxicity BioAssay Kit (Lonza) by following the kit instructions (Table S1).
Cell lysis and digestion by FASP
The cell pellets were lysed in 200 µl of 4 % SDS and 0.1 M dithiothreitol (DTT) in 0.1 M Tris HCl, pH 7.6.
First, the samples were incubated at 95 °C for 5 min to inactivate the virus and to denature the
proteins, followed by a sonication step to reduce the viscosity of the cell pellet. The samples were
then centrifuged at 16 000 x g at 20 °C for 20 min, and the supernatant containing the extracted
proteins was collected.  For detergent removal and protein digestion slightly modified filter assisted
sample preparation (FASP) protocol was used (Wiśniewski et al., 2009). Around 60 µg of protein lysate
was added in Microcon-30 kDa filter units YM-30 (Millipore). Then 400 µl of 8 M urea in 0.1 M Tris/HCl,
ph 8.5 (UA) was added to each filter and centrifuged at 8 000 x g at 20 °C for 25 min. This step was
repeated twice. Right after, 300 µl of 0.05 M iodoacetamide (IAA) in UA was added to each filter and
were incubated in dark for 20 min. The filters were then washed twice with 400 µl of UA by
centrifuging the samples at 8 000 x g at 20 °C for 30 min. The buffer was then changed to digestion
buffer by centrifuging twice with 400 µl of 10 % acetonitrile in 25 mM Tris/HCl, pH 8.0 at 8 000 x g at
20 °C for 30 min. Trypsin (Promega) was then added to each filter with 300 µl of digestion buffer. The
used enzyme-protein ratio was 1:30. The samples were incubated overnight at 37 °C and the peptides
were collected in the following day by centrifuging at 8 000 x g at 20 °C for 10 min that was followed
by a rinsing step by centrifuging 250 µl of digestion buffer at 8 000 x g at 20 °C for 30 min. The samples
were then dried and reconstituted for desalting with 1 ml of 0.1 % TFA. The desalting step was
performed with Sep-Pak® C18 96-well plate (Waters) after which the samples were dried using a speed
vacuum centrifuge. For the MS analyses, the dried samples were dissolved into 2 % FA 2 % ACN and
the protein concentration was determined using NanoDrop-1000 UV-spectrometer (Thermo
Scientific). Approximately 250 ng of each sample was injected to LC-MS/MS analysis. All samples were
analyzed in technical triplicates in a randomized order.
Cell culture supernatant digestion
First, 7 ml of cell culture media for each sample was concentrated in 10 kDa Amicon Ultra-15
Centrifugal filter units (Merck Millipore) (3 220 g at 4 °C for 1h). The concentrated samples were
collected and heated at 95 °C for 5 min to inactivate the virus. The samples were then further
concentrated by using 3 kDa Amicon Ultra-0.5 Centrifugal filter units (Merck Millipore) (14 000 x g at
20 °C for 1 h). Right after, 250 µl of 8 M urea in 0.1 M ammonium bicarbonate (AmBic) was added to
the filters and centrifuged at 14 000 x g at 20 °C for 45 min to change the buffer. The remaining sample
inside the filter unit was collected and transferred to a new tube. The disulphide bonds were then
reduced by adding 5 mM final concentration of DTT in 0.1 M AmBic and incubating the samples at 37
°C for 1h. Subsequently, an alkylation step was performed by adding 13 mM final concentration of 1
M IAA in 0.1 M AmBic to each sample and incubating the samples in dark at room temperature for 30
min.  The urea concentration in each sample was decreased below 1.5 M by adding 0.1 M AmBic. To
each sample we added around 1:20 enzyme-substrate ratio of trypsin (Promega) and incubated the
samples at 37 °C overnight. In the following day the trypsin activity was stopped by reducing the pH
below pH 3. The samples were then desalted using Sep-Pak® C18 cartridges (Waters) and dried in a
speed vacuum centrifuge. The dried samples were then reconstituted and the protein amount was
determined as described in the previous section. The loading and LC-MS/MS analysis were likewise
done as described earlier.
Mass spectrometric analyses
The peptide samples were measured by Q Exactive™ HF Hybrid Quadrupole-Orbitrap™ mass
spectrometer (Thermo Fischer Scientific) that was interfaced with EASY-nLC 1200 liquid
chromatograph (Thermo Fischer Scientific) and a nano-electrospray ion source (Thermo Fischer
Scientific). The peptides were directly loaded into an in-house packed 40 cm 75 μm ID capillary column
with 1.9 μm Reprosil-Pur C18 beads (Dr. Maisch) in buffer A (0.1 % (v/v) formic acid). Subsequently, the
peptides were separated using a 110-min gradient starting from linear 75-min gradient of 7-25 % of
buffer B (0.1 % (v/v) formic acid, 80 % (v/v) acetonitrile), followed by 15-min increase to 35 % of buffer
B and then 10-min increase to 100 % of buffer B before 10-min washing step with 100 % buffer B. The
column temperature was kept at 60 °C throughout the runs using an in-house column oven. The full
scan resolution was set to 120 000 at m/z 200 and the MS spectra were collected in the 300-1700 m/z
range with an ion target value of 3 x 106 and maximum injection time of 100 ms. The 12 most intense
precursors were selected for fragmentation that was performed by high energy C-trap dissociation
(HCD) with a normalized collision energy of 27 eV. MS2 scans were performed at a resolution of 15
000 at m/z 200, in the range 200-2000 m/z for 200 ms and with an ion target value of 5 x 104. To avoid
repeated selection of precursor ions dynamic exclusion was set to 20 s.
Proteomics data processing and statistical analysis
MaxQuant software (Cox and Mann, 2008) version 1.5.5.1 was used for a data processing of the raw
MS files obtained from the LC-MS/MS analyses. The in-built Andromeda search engine (Cox et al.,
2011) was used to search the peptide lists against a combined database of SwissProt human and
TrEMBL enterovirus sequences (version June 2018, 80862 entries) with added iRT peptide sequences
and a common contaminants database. Label-free quantification was performed with the LFQ ratio
count of 2.  N-terminal acetylation and methionine oxidation was used as a variable modifications and
cysteine carbamidomethylation as a fixed modification. For both proteins and peptides the false
discovery rate (FDR) was set to 1 % and was determined by searching a reverse database. The
minimum peptide length was set to seven amino acids. The enzyme specificity was set to trypsin and
the maximum number of allowed missed cleavages was two. In order to transfer the peptide
identification across the raw files a “match between runs” feature was used. Otherwise the default
settings were used.
The processed data from MaxQuant was analyzed with Perseus software (Tyanova et al., 2016) using
the normalised LFQ intensities. First, proteins identified only based on modified peptides and
identifications from the reversed decoy database removed, followed by manual removal of potential
contaminant proteins not present in the used human and enterovirus sequence database. Also,
minimum two razor and/or unique peptide identifications were required for each protein. The median
LFQ intensities of the three technical replicates were calculated with the requirement of minimum of
two valid values per sample. Finally, only proteins quantified in at least three samples were kept.
Unpaired Student’s t-test implemented in Perseus (Tyanova et al., 2016) was applied to identify
differentially expressed proteins. Proteins with false discovery rate (FDR) < 5 % and |fold-change| >
1.5 were considered significantly differentially expressed.
Quantitative real time-PCR
Total RNA was extracted using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen) and treated in-
column with DNase (RNase-Free Dnase Set; QIAGEN) for 15 minutes. The removal of genomic DNA
was ascertained by treating the samples with DNase I (Invitrogen) before cDNA synthesis with
SuperScript II Reverse Transcriptase (Invitrogen). Quantitative real time-PCR (qPCR) was performed
using KAPA™ probe fast qPCR Master Mix (Kapa Biosystems) and Universal ProbeLibrary probes
(Roche Applied Science) with custom ordered primers (Table S7). The qPCR runs were analyzed with
Applied Biosystems QuantStudio 12K Flex Real-Time PCR System (10 minutes enzyme activation and
40 cycles of 15 sec 95°C, 1 min 60°C). All reactions were performed in triplicate. The cycle threshold
(Ct) values of the target transcripts were normalized against the signal acquired with GAPDH
(housekeeping gene) and expressed as deltaCt = (CtGene−CtGAPDH).
Detection of IFIH1 expression by in situ hybridization
A commercial QuantiGene ViewRNA in situ hybridization –technique was applied to detect a viral
pattern recognition receptor IFIH1/MDA5 (#VA1-13031) in FFPE samples. These FFPE samples were
collected from two different time points (102 days and 228 days post infection). A standard protocol,
according to the manufacturer’s instructions was performed, as previously described (Laiho et al.,
2015). Briefly, FFPE samples were deparaffinized, dehydrated and rehydrated, followed by a 10 min
boiling and a 10 min proteinase step. Targets were hybridized for 2 hrs at RT. Target-specific
hybridization was followed by signal amplification using specific oligonucleotides conjugated to
alkaline phosphatase. Fast Red substrate was used for detection under both bright-field and
fluorescent lights. Imaging was done using Olympus BX-60 microscope.
Mitochondrial visualization
Mitochondrial network morphology was visualized from live cell samples of persistently infected cells
and non-infected control cells. Prior to the mitochondrial staining the live cells were plated on cover
slip Petri dish, pre-coated with 2% gelatin (Sigma-Aldrich). Mitochondria of live persistently infected
cells were stained with Mitotracker Red CMXRos (Life Technologies), which accumulates in the
organelle based on the membrane potential. Mitotracker was dissolved into DMSO to prepare a 40
µM stock solution. Mitotracker stock solution was further diluted into complete DMEM, to obtain a
final concentration of 20 nM; and incubated with the cells for 45 min at 37 ˚C and 5% CO2. The dye
was removed by rinsing with PBS. Imaging was done using a Olympus IX51 Fluorescence Microscope.
Three biological repeats of CVB1 ATCC persistent infection model and four biological repeats of non-
infected control cells and CVB1 10796 persistent infection model were imaged. From each sample set,
ten images were captured and analyzed. The cells were divided into four categories based on their
mitochondrial network morphology. The categories were elongated filaments, filaments,
intermediate and fragmented network. Elongated filaments category included cells with long
filaments as mitochondrial network. Filaments category included all cells with shorter filamentous
mitochondrial network but with very low to no fragmented mitochondria. Intermediate category
included cells with a clear mixture of elongated and fragmented mitochondria. Fragmented category
included cells with large majority of fragmented mitochondrial network. Additionally, out focused cells
and uncategorized cells were included in the analysis while not included in the data presented in the
figures. Uncategorized cells covered 15% of uninfected control cells, 3% of CVB1 infected cells and 4%
CVB1 10796 infected cells. Percentages of cells belonging to each category were calculated for each
biological repeat, and average and standard deviations of these were calculated separately for each
condition. Statistical significance was estimated using Z-test.
Western blot analyses
Western blot analyses were performed using the same cell lysates that were used for the proteomics
analyses. After boiling the samples with 6× loading dye (330 mM Tris-HCl, pH 6.8; 330 mM SDS; 6% β-
ME; 170 μM bromophenol blue; 30% glycerol), the samples were loaded on Mini-PROTEAN TGX
Precast Protein Gels (BioRad Laboraotries) and transferred to PVDF membranes (Trans-Blot Turbo
Transfer Packs, BioRad Laboratories). The primary antibodies used: eIF4G (#2617, Cell Signaling
Technologies) and beta-actin (A5441, Sigma-Aldrich).
Functional data analyses
Functional enrichment analyses were performed using DAVID Functional Annotations (Huang et al.,
2009) and Ingenuity Pathway Analysis (IPA, www.qiagen.com/ingenuity, Qiagen) tools. Gene Ontology
classes with DAVID FDR <0.05 and IPA pathways with p-value <0.01 were considered as significantly
enriched.
SignalP
A neural network based SignalP (version 4.1) software was used to predict proteins with a secretory
signal peptide (Petersen et al., 2011). Both SignalP-TM and SignalP-noTM networks were used to
distinguish between signal peptides and transmembrane regions.
Data availability
The raw mass spectrometry data have been deposited to the ProteomeXchange Consortium
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository (Vizcaíno et al.,
2012) with the dataset identifiers PXD012153 and PXD012154.
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